A new stroke within 90 days (primary efficacy outcome) occurred in 222 patients (7.3%) in the clopidogrel–aspirin group and in 279 patients (9.2%) in the aspirin group (marginal estimated hazard ...

Because aspirin can contribute to the danger of big bleeds like aneurysms, researchers wanted to know whether it might also be a factor in more subtle blood loss: the kind that may lead to anemia ...

In a large, long-term trial, cilostazol was as effective as aspirin at preventing recurrent stroke and was associated with fewer hemorrhages. Antiplatelet drugs have an established role in ...

The researchers found no difference in fracture risk between the two groups. In the aspirin group, 8.6% experienced falls and fractures. The placebo group saw 9.5%.

SAN FRANCISCO — In patients with ACS, stopping aspirin for ticagrelor monotherapy within 1 month of receiving a drug-eluting stent did not increase adverse CV and bleeding events compared with ...

By the median follow-up of 33.8 months, 253 IDFS events had been recorded, with slightly more events in the aspirin group than in the placebo group, but without statistical significance.

(This study used low-dose aspirin -- 100 mg -- rather than the full-dose of 325 mg that you are taking.) The risk of bleeding was about the same among the aspirin group and the Xarelto group.

Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly. Annals of Internal Medicine, 2023; DOI: 10.7326/M23-0675 ...